{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T22:36:04Z","timestamp":1762641364686},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,8,24]],"date-time":"2010-08-24T00:00:00Z","timestamp":1282608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2010,8,24]],"date-time":"2010-08-24T00:00:00Z","timestamp":1282608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1007\/s10637-010-9523-2","type":"journal-article","created":{"date-parts":[[2010,8,23]],"date-time":"2010-08-23T04:07:24Z","timestamp":1282536444000},"page":"368-375","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity"],"prefix":"10.1007","volume":"30","author":[{"given":"Seok Jin","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kihyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byung Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jooryung","family":"Huh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Hae","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keunchil","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheolwon","family":"Suh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won Seog","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,8,24]]},"reference":[{"key":"9523_CR1","doi-asserted-by":"crossref","unstructured":"(1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma. The Non-Hodgkin\u2019s Lymphoma Classification Project. Blood 89:3909\u20133918","DOI":"10.1182\/blood.V89.11.3909"},{"key":"9523_CR2","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1023\/A:1008375931236","volume":"10","author":"NL Harris","year":"1999","unstructured":"Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD (1999) The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol 10:1419\u20131432","journal-title":"Ann Oncol"},{"key":"9523_CR3","first-page":"76","volume":"92","author":"C Gisselbrecht","year":"1998","unstructured":"Gisselbrecht C, Gaulard P, Lepage E, Coiffier B, Briere J, Haioun C, Cazals-Hatem D, Bosly A, Xerri L, Tilly H, Berger F, Bouhabdallah R, Diebold J (1998) Prognostic significance of T-cell phenotype in aggressive non-Hodgkin\u2019s lymphomas. Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte (GELA). Blood 92:76\u201382","journal-title":"Blood"},{"key":"9523_CR4","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","volume":"103","author":"A Gallamini","year":"2004","unstructured":"Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, Morabito F, Martelli M, Brusamolino E, Iannitto E, Zaja F, Cortelazzo S, Rigacci L, Devizzi L, Todeschini G, Santini G, Brugiatelli M, Federico M (2004) Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 103:2474\u20132479. doi:10.1182\/blood-2003-09-3080","journal-title":"Blood"},{"key":"9523_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0959-8049(01)00344-6","volume":"38","author":"K Kim","year":"2002","unstructured":"Kim K, Kim WS, Jung CW, Im YH, Kang WK, Lee MH, Park CH, Ko YH, Ree HJ, Park K (2002) Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the Revised European-American lymphoma (REAL) classification. Eur J Cancer 38:75\u201381","journal-title":"Eur J Cancer"},{"key":"9523_CR6","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1136\/jcp.47.4.313","volume":"47","author":"JR Salisbury","year":"1994","unstructured":"Salisbury JR, Rapson NT, Codd JD, Rogers MV, Nethersell AB (1994) Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin\u2019s lymphomas. J Clin Pathol 47:313\u2013317","journal-title":"J Clin Pathol"},{"key":"9523_CR7","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1182\/blood-2003-10-3389","volume":"103","author":"G Enblad","year":"2004","unstructured":"Enblad G, Hagberg H, Erlanson M, Lundin J, MacDonald AP, Repp R, Schetelig J, Seipelt G, Osterborg A (2004) A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 103:2920\u20132924. doi:10.1182\/blood-2003-10-3389","journal-title":"Blood"},{"key":"9523_CR8","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1200\/JCO.1996.14.2.534","volume":"14","author":"M Martelli","year":"1996","unstructured":"Martelli M, Vignetti M, Zinzani PL, Gherlinzoni F, Meloni G, Fiacchini M, De Sanctis V, Papa G, Martelli MF, Calabresi F, Tura S, Mandelli F (1996) High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin\u2019s lymphoma with partial response to front-line chemotherapy: a prospective randomized Italian multicenter study. J Clin Oncol 14:534\u2013542","journal-title":"J Clin Oncol"},{"key":"9523_CR9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1046\/j.0902-4441.2004.00171.x","volume":"72","author":"A Olivieri","year":"2004","unstructured":"Olivieri A, Brunori M, Capelli D, Montanari M, Massidda D, Gini G, Lucesole M, Poloni A, Offidani M, Candela M, Centurioni R, Leoni P (2004) Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients: an intention to mobilize and transplant analysis. Eur J Haematol 72:10\u201317. doi:10.1046\/j.0902-4441.2004.00171.x","journal-title":"Eur J Haematol"},{"key":"9523_CR10","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1093\/annonc\/mdn726","volume":"20","author":"SJ Kim","year":"2009","unstructured":"Kim SJ, Kim K, Kim BS, Suh C, Huh J, Ko YH, Kim WS (2009) Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a phase II prospective study. Ann Oncol 20:390\u2013392","journal-title":"Ann Oncol"},{"key":"9523_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1\u201310","journal-title":"Control Clin Trials"},{"key":"9523_CR12","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244","journal-title":"J Clin Oncol"},{"key":"9523_CR13","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/sj.bmt.1702867","volume":"27","author":"AK Blystad","year":"2001","unstructured":"Blystad AK, Enblad G, Kvaloy S, Berglund A, Delabie J, Holte H, Carlson K, Kvalheim G, Bengtsson M, Hagberg H (2001) High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant 27:711\u2013716. doi:10.1038\/sj.bmt.1702867","journal-title":"Bone Marrow Transplant"},{"key":"9523_CR14","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1080\/1042819022386806","volume":"43","author":"CL Huang","year":"2002","unstructured":"Huang CL, Lin ZZ, Su IJ, Chao TY, Tien HF, Chang MC, Huang MC, Kao WY, Tang JL, Yeh KH, Wang CH, Hsu CH, Liu MY, Cheng AL (2002) Combination of 13-cis retinoic acid and interferon-alpha in the treatment of recurrent or refractory peripheral T-cell lymphoma. Leuk Lymphoma 43:1415\u20131420","journal-title":"Leuk Lymphoma"},{"key":"9523_CR15","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1080\/10428190500178266","volume":"46","author":"BB Park","year":"2005","unstructured":"Park BB, Kim WS, Lee J, Park KW, Kang JH, Lee SH, Park JO, Kim K, Jung CW, Park YS, Im YH, Kang WK, Ko YH, Lee MH, Park K (2005) IMVP-16\/Pd followed by high-dose chemotherapy and autologous stem cell transplantation as a salvage therapy for refractory or relapsed peripheral T-cell lymphomas. Leuk Lymphoma 46:1743\u20131748. doi:10.1080\/10428190500178266","journal-title":"Leuk Lymphoma"},{"key":"9523_CR16","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","volume":"110","author":"A Gallamini","year":"2007","unstructured":"Gallamini A, Zaja F, Patti C, Billio A, Specchia MR, Tucci A, Levis A, Manna A, Secondo V, Rigacci L, Pinto A, Iannitto E, Zoli V, Torchio P, Pileri S, Tarella C (2007) Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 110:2316\u20132323. doi:10.1182\/blood-2007-02-074641","journal-title":"Blood"},{"key":"9523_CR17","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s00280-007-0469-9","volume":"60","author":"JG Kim","year":"2007","unstructured":"Kim JG, Sohn SK, Chae YS, Cho YY, Yang DH, Lee JJ, Kim HJ, Shin HJ, Chung JS, Cho GJ, Lee WS, Joo YD, Sohn CH, Oh SJ (2007) Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. Cancer Chemother Pharmacol 60:129\u2013134. doi:10.1007\/s00280-007-0469-9","journal-title":"Cancer Chemother Pharmacol"},{"key":"9523_CR18","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00277-008-0544-2","volume":"88","author":"Y Lee","year":"2009","unstructured":"Lee Y, Uhm JE, Lee HY, Park MJ, Kim H, Oh SJ, Jang JH, Kim K, Jung CW, Ahn YC, Park K, Ko YH, Kim WS (2009) Clinical features and prognostic factors of patients with \u201cperipheral T cell lymphoma, unspecified\u201d. Ann Hematol 88:111\u2013119. doi:10.1007\/s00277-008-0544-2","journal-title":"Ann Hematol"},{"key":"9523_CR19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1080\/10428190601016167","volume":"48","author":"ST Chang","year":"2007","unstructured":"Chang ST, Lu CL, Chuang SS (2007) CD52 expression in non-mycotic T- and NK\/T-cell lymphomas. Leuk Lymphoma 48:117\u2013121. doi:10.1080\/10428190601016167","journal-title":"Leuk Lymphoma"},{"key":"9523_CR20","doi-asserted-by":"publisher","first-page":"566","DOI":"10.3324\/haematol.10767","volume":"92","author":"PP Piccaluga","year":"2007","unstructured":"Piccaluga PP, Agostinelli C, Righi S, Zinzani PL, Pileri SA (2007) Expression of CD52 in peripheral T-cell lymphoma. Haematologica 92:566\u2013567","journal-title":"Haematologica"},{"key":"9523_CR21","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1080\/10428190701760029","volume":"49","author":"D Hui","year":"2008","unstructured":"Hui D, Lam W, Toze C, Delorme M, Noble M, Klimo P, Sutherland J, Gill K, Connors J, Sehn L (2008) Alemtuzumab in clinical practice: a British Columbia experience. Leuk Lymphoma 49:218\u2013226. doi:10.1080\/10428190701760029","journal-title":"Leuk Lymphoma"},{"key":"9523_CR22","doi-asserted-by":"publisher","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","volume":"99","author":"MJ Keating","year":"2002","unstructured":"Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, Albitar M, Brettman L, Santabarbara P, Wacker B, Rai KR (2002) Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99:3554\u20133561","journal-title":"Blood"},{"key":"9523_CR23","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/sj.leu.2403258","volume":"18","author":"J Lundin","year":"2004","unstructured":"Lundin J, Porwit-MacDonald A, Rossmann ED, Karlsson C, Edman P, Rezvany MR, Kimby E, Osterborg A, Mellstedt H (2004) Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia 18:484\u2013490. doi:10.1038\/sj.leu.2403258","journal-title":"Leukemia"},{"key":"9523_CR24","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.3324\/haematol.12465","volume":"93","author":"A Nosari","year":"2008","unstructured":"Nosari A, Tedeschi A, Ricci F, Montillo M (2008) Characteristics and stage of the underlying diseases could determine the risk of opportunistic infections in patients receiving alemtuzumab. Haematologica 93:e30\u201331. doi:10.3324\/haematol.12465","journal-title":"Haematologica"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-010-9523-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-010-9523-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-010-9523-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-010-9523-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T05:07:16Z","timestamp":1678511236000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-010-9523-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,24]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["9523"],"URL":"https:\/\/doi.org\/10.1007\/s10637-010-9523-2","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,24]]},"assertion":[{"value":"7 July 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}